700 related articles for article (PubMed ID: 16084657)
21. Cellular mechanisms of opioid tolerance: studies in single brain neurons.
Christie MJ; Williams JT; North RA
Mol Pharmacol; 1987 Nov; 32(5):633-8. PubMed ID: 2824980
[TBL] [Abstract][Full Text] [Related]
22. Acute and chronic effects of opioids on delta and mu receptor activation of G proteins in NG108-15 and SK-N-SH cell membranes.
Breivogel CS; Selley DE; Childers SR
J Neurochem; 1997 Apr; 68(4):1462-72. PubMed ID: 9084416
[TBL] [Abstract][Full Text] [Related]
23. After GM1 ganglioside treatment of sensory neurons naloxone paradoxically prolongs the action potential but still antagonizes opioid inhibition.
Crain SM; Shen KF
J Pharmacol Exp Ther; 1992 Jan; 260(1):182-6. PubMed ID: 1731037
[TBL] [Abstract][Full Text] [Related]
24. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment.
Crain SM; Shen KF
Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10540-4. PubMed ID: 7479836
[TBL] [Abstract][Full Text] [Related]
25. Mu opiate receptor down-regulation by morphine and up-regulation by naloxone in SH-SY5Y human neuroblastoma cells.
Zadina JE; Chang SL; Ge LJ; Kastin AJ
J Pharmacol Exp Ther; 1993 Apr; 265(1):254-62. PubMed ID: 8097244
[TBL] [Abstract][Full Text] [Related]
26. Role of spinal mu opioid receptors in the development of morphine tolerance and dependence.
DeLander GE; Portoghese PS; Takemori AE
J Pharmacol Exp Ther; 1984 Oct; 231(1):91-6. PubMed ID: 6092607
[TBL] [Abstract][Full Text] [Related]
27. Evidence that opioids may have toll-like receptor 4 and MD-2 effects.
Hutchinson MR; Zhang Y; Shridhar M; Evans JH; Buchanan MM; Zhao TX; Slivka PF; Coats BD; Rezvani N; Wieseler J; Hughes TS; Landgraf KE; Chan S; Fong S; Phipps S; Falke JJ; Leinwand LA; Maier SF; Yin H; Rice KC; Watkins LR
Brain Behav Immun; 2010 Jan; 24(1):83-95. PubMed ID: 19679181
[TBL] [Abstract][Full Text] [Related]
28. Chronic naloxone-induced supersensitivity affects neither tolerance to nor physical dependence on morphine at hypothalamus-pituitary-adrenocortical axis.
Alcaraz C; Vargas ML; Milanés MV
Neuropeptides; 1996 Feb; 30(1):29-36. PubMed ID: 8868296
[TBL] [Abstract][Full Text] [Related]
29. Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity.
DeHaven-Hudkins DL; Burgos LC; Cassel JA; Daubert JD; DeHaven RN; Mansson E; Nagasaka H; Yu G; Yaksh T
J Pharmacol Exp Ther; 1999 Apr; 289(1):494-502. PubMed ID: 10087042
[TBL] [Abstract][Full Text] [Related]
30. 3H-naloxone benzoylhydrazone binding in MOR-1-transfected Chinese hamster ovary cells: evidence for G-protein-dependent antagonist binding.
Brown GP; Pasternak GW
J Pharmacol Exp Ther; 1998 Jul; 286(1):376-81. PubMed ID: 9655882
[TBL] [Abstract][Full Text] [Related]
31. Modulation of Ca2+/calmodulin-dependent protein kinase II activity by acute and chronic morphine administration in rat hippocampus: differential regulation of alpha and beta isoforms.
Lou L; Zhou T; Wang P; Pei G
Mol Pharmacol; 1999 Mar; 55(3):557-63. PubMed ID: 10051541
[TBL] [Abstract][Full Text] [Related]
32. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
Eissenberg T; Greenwald MK; Johnson RE; Liebson IA; Bigelow GE; Stitzer ML
J Pharmacol Exp Ther; 1996 Feb; 276(2):449-59. PubMed ID: 8632309
[TBL] [Abstract][Full Text] [Related]
33. Differential blockade of morphine and morphine-6 beta-glucuronide analgesia by antisense oligodeoxynucleotides directed against MOR-1 and G-protein alpha subunits in rats.
Rossi GC; Standifer KM; Pasternak GW
Neurosci Lett; 1995 Sep; 198(2):99-102. PubMed ID: 8592651
[TBL] [Abstract][Full Text] [Related]
34. Chronic opioid treatment of neuroblastoma x dorsal root ganglion neuron hybrid F11 cells results in elevated GM1 ganglioside and cyclic adenosine monophosphate levels and onset of naloxone-evoked decreases in membrane K+ currents.
Wu G; Fan SF; Lu ZH; Ledeen RW; Crain SM
J Neurosci Res; 1995 Nov; 42(4):493-503. PubMed ID: 8568936
[TBL] [Abstract][Full Text] [Related]
35. Inhibition by naloxone of tolerance and dependence in mice treated acutely and chronically with morphine.
Yano I; Takemori AE
Res Commun Chem Pathol Pharmacol; 1977 Apr; 16(4):721-34. PubMed ID: 16322
[TBL] [Abstract][Full Text] [Related]
36. Opioid receptor regulation in mice.
Yoburn BC; Billings B; Duttaroy A
J Pharmacol Exp Ther; 1993 Apr; 265(1):314-20. PubMed ID: 8386239
[TBL] [Abstract][Full Text] [Related]
37. Studies on the abstinence-like overshoot following reversal of the potent 19-isoamyl derivative of etorphine with naloxone. A comparison with the opioids fentanyl and alfentanil.
Freye E; Neruda B; Smith OW
Arzneimittelforschung; 1997 Jan; 47(1):6-9. PubMed ID: 9037435
[TBL] [Abstract][Full Text] [Related]
38. Is the reduced efficacy of morphine in diabetic rats caused by alterations of opiate receptors or of morphine pharmacokinetics?
Courteix C; Bourget P; Caussade F; Bardin M; Coudore F; Fialip J; Eschalier A
J Pharmacol Exp Ther; 1998 Apr; 285(1):63-70. PubMed ID: 9535995
[TBL] [Abstract][Full Text] [Related]
39. Interactions of ketamine, naloxone and morphine in the rat.
Fidecka S
Pol J Pharmacol Pharm; 1987; 39(1):33-40. PubMed ID: 3671186
[TBL] [Abstract][Full Text] [Related]
40. Alterations in the expression of G-proteins and regulation of adenylate cyclase in human neuroblastoma SH-SY5Y cells chronically exposed to low-efficacy mu-opioids.
Ammer H; Schulz R
Biochem J; 1993 Oct; 295 ( Pt 1)(Pt 1):263-71. PubMed ID: 8216227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
